Researcher Database

（Last updated : 2025-04-07 14:10:59）　

KITAMURA YOSHIHISA

Department / Course College of Pharmaceutical Sciences Department of Pharmaceutical Sciences

Title / Position Professor

Other Affiliations
1.	Graduate School of Pharmacy

Academic background
1.	～1983/03	Department of General Pharmacology │ School of Medicine │ Hiroshima University │ Graduated
2.	～1985/03	Doctoral Program (1st Semester) │ Biopharmacy Major │ School of Medicine │ Hiroshima University │ Completed
3.	1985/03 Degree Acquisition	│ Hiroshima University M.Pharm.
4.	～1987/06	Doctoral Program (2nd Semester) │ Department of Pharmaceutical Sciences │ Graduate School of Pharmaceutical Sciences │ Hokkaido University │ Unfinished
5.	1988/09 Degree Acquisition	│ Hokkaido University Ph.D. in Pharmaceutical Sciences

Research activities
1.		The Pharmaceutical Society of Japan
2.		The Japanese Pharmacological Society
3.		The Japanese Society for Regenerative Medicine
4.		The Japanese Society for Neurochemistry
5.		The Japanese Society of Neuropsychopharmacology

Subject of research
1.	Synucleionopathy and DJ-1 Protein
2.	Neural Network Revitalization in Planarian Brain
3.	Alzheimer's Disease and Microglia

Research summary
Elucidation of the mechanism for the outbreak of neurodegenerative disease and the development of drastic remedy strategy Parkinson’s disease, Alzheimer’s disease, etc., are well known as refractory neurodegenerative diseases. We are conducting our studies to develop a drastic remedy and a new treatment drug for these neurodegenerative diseases. The brain contains nerve cells that adjust bodily functions, glia cells (microglia, astrocytes, oligodendrocytes, and NG2 glia cells) to support them, and cerebral blood vessels to supply nutrition. The three coordinate with each other to conduct human brain activities. However, aging and hereditary cause the homeostasis of the brain to break down and when aggregate of disease-specific denatured proteins (Lewy body, senile plaques, neurofibrillary tangles, etc.) are formed, neurodegenerative diseases like Parkinson’s and Alzheimer’s disease develop. With the arrival of ultra aging society with fewer children today, development of drugs to treat neurodegenerative diseases whose onset increase with aging is a task to be addressed immediately. Although many pharmaceutical companies have entered this field, there has not been any discovery of a specific medicine where drastic remedy can be expected. We are conducting studies for the analysis of its onset mechanism for the development of a new treatment drug, and the search for drug discovery targets using animal (rat, mouse) and human derived cultured cells. Currently, experiments are being made under research themes of “Alzheimer’s disease and microglia” and “Parkinson’s disease and DJ-1 protein”. In addition, from nerve regeneration studies of planarian brain having a very high regeneration capacity, we are targeting at elucidation of three-dimensional autonomous regeneration mechanism of cranial nerve network. We dream of linking this to development of a drastic remedy for neurodegenerative diseases.

Books
1.	2017/07	DJ-1/PARK7 Protein: Parkinson's Dosease, Cancer and Oxidative Stress-Induced Diseases (H. Ariga & S.M.M. Iguchi-Ariga, eds) Chapter 12: Therapeutic activities of DJ-1 and Its binding compounds against neurodegenerative diseases. │ ,pp.187-202
2.	2013/07	Neural Stem Cells (L. Bonfanti, ed.) Chapter 10: A Survey of the molecular basis for the generation of functional dopaminergic neurons from pluripotent stem cells: Insights from regenerative biology and regenerative medicine. │ ,pp.271-286
3.	2013	Animal Models in Human Disease: Applications, Outcomes and Controversies (S.A. Murray, ed.) Development of Cell Therapeutic Strategies for Alzheimer’s Disease Using Animal Models. │ ,pp.87-103
4.	2012/10	Microglia: Functions and Roles in Disease (C. Kaur & L. Eng-Ang, eds) Chapter 8: Microglial functions against amyloid-β accumulation in brains of Alzheimer’s disease. │ ,pp.153-165
5.	2012/07	Neural Stem Cells and Therapy ( ) Chapter 7: Regeneration of brain and dopaminergic neurons utilizing pluripotent stem cells: lessons from planarians. │ ,pp.141-158
Display All（14）

Papers
1.	2022	Lipoxin A4 receptor stimulation attenuates neuroinflammation in a mouse model of intracerebral hemorrage. │ Brain Sciences │ 12,pp.162
2.	2022	Nicotinic acetylcholine receptors and microglia as therapeutic and imaging targets in Alzheimer’s disease │ Molecules │ 27,pp.2780
3.	2021/01/19	MEK/ERK signaling regulates reconstitution of the dopaminergic nerve circuit in the planarian Dugesia japonica │ Neurochemical Research │
4.	2021	Kaempferol has potent protective and antifibrillogenic effectsfor α-synuclein neurotoxicity in vitro. │ Molecular Sciences │ 22 (21),pp.11484
5.	2020/11	Neuroprotective effects of 5-aminolevulinic acid against neurodegeneration in rat models of Parkinson's disease and stroke. │ J. Pharmacol. Sci., │ 144 (3),pp.183-187
Display All（192）

Academic conference presentation
1.	2019/07	Analysis of the functions of leukotriene B4 and lipoxin A4 to the neutrophil invasion into hematoma in vitro model of intracerebral hemorrhage
2.	2019/07	Promotion of microglial Aβ phagocytosis by TGF-β1 secreted from mouse bone marrow-derived cells
3.	2019/06	カキシメジ毒成分の獲得を目指した高速向流クロマトグラフィーによる単離精製法の構築
4.	2019/03	Effect of lipoxin A4 for pathology of intracerebral hemorrhage mediated by microglial activation
5.	2019/03	Effects of nicotinic acetylcholine receptors on neurons, microglia, and bone marrow-derived microglia-like cells for the treatment of Alzheimer's disease
Display All（19）

Competitive grants, etc. (exc. KAKENHI)
1.	1998/10 ～ 1999/09	Second messenger mediated regulation of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) expression in microglia and in brain │ Research by External Competitive Fund │ Alexander von Humboldt-Stiftung: Research Fellowship

E-Mail Address